Who are Accolate's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Onon, Montelukast,mometazon froat, MK0476; montelukast sodium, Comparator: Montelukast, Singulair, ICS/LABA and Montelukast.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/zafirlukast.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-15 · How we verify

Accolate — Competitive Intelligence Brief

Accolate (ZAFIRLUKAST) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Leukotriene Receptor Antagonist [EPC]. Area: Cardiovascular.

marketed Leukotriene Receptor Antagonist [EPC] Cysteinyl leukotriene receptor 1 Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Accolate (ZAFIRLUKAST) — Strides Pharma Intl.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Accolate TARGET	ZAFIRLUKAST	Strides Pharma Intl	marketed	Leukotriene Receptor Antagonist [EPC]	Cysteinyl leukotriene receptor 1	1996-01-01
Onon	PRANLUKAST		marketed	pranlukast	Cysteinyl leukotriene receptor 1	1995-01-01
Montelukast,mometazon froat	Montelukast,mometazon froat	Istanbul Training and Research Hospital	marketed	Leukotriene receptor antagonist + inhaled corticosteroid combination	Cysteinyl leukotriene receptor 1 (CysLT1) and glucocorticoid receptor
MK0476; montelukast sodium	MK0476; montelukast sodium	Organon and Co	marketed	Cysteinyl leukotriene receptor antagonist (LTRA)	CysLT1 (cysteinyl leukotriene receptor 1)
Comparator: Montelukast	Comparator: Montelukast	Organon and Co	marketed	Cysteinyl leukotriene receptor antagonist (LTRA)	CysLT1 (cysteinyl leukotriene receptor 1)
Singulair	montelukast	Merck & Co.	marketed	Leukotriene receptor antagonist (LTRA)	Cytochrome P450 2C8, Adenosine receptor A3, Cysteinyl leukotriene receptor 2	1998-02-20
ICS/LABA and Montelukast	ICS/LABA and Montelukast	The First Affiliated Hospital of Guangzhou Medical University	marketed	ICS/LABA combination with leukotriene receptor antagonist	Glucocorticoid receptor, beta-2 adrenergic receptor, cysteinyl leukotriene receptor (CysLT1)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Leukotriene Receptor Antagonist [EPC] class)

Strides Pharma Intl · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Accolate — Competitive Intelligence Brief. https://druglandscape.com/ci/zafirlukast. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab